Endo International

aid: endo-international
url: https://raw.githubusercontent.com/api-evangelist/endo-international/refs/heads/main/apis.yml
name: Endo International
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/endo-international.png
tags:
- Pharmaceuticals
- Specialty Pharma
- Generics
- Sterile Injectables
- Urology
- Orthopedics
- Chapter 11
- Opioid Settlement
description: Endo International was a specialty pharmaceutical company best known for Xiaflex (collagenase clostridium histolyticum),
  branded urology and orthopedic products, and a large sterile-injectables and generics business (Par Pharmaceutical). Endo
  filed Chapter 11 in August 2022 amid mass opioid litigation tied to its legacy Opana ER franchise, and emerged in April
  2024 as the private company Endo, Inc., owned by its former creditors. On July 31, 2025, Endo combined with Mallinckrodt;
  the merged group then separated in November 2025 into two independent companies — Keenova Therapeutics (specialty branded
  therapeutics, including the former Endo Xiaflex/urology/orthopedics portfolio and Mallinckrodt specialty brands) and Par
  Health (generics, sterile injectables, and pharmaceutical Active Pharmaceutical Ingredients manufacturing). Endo no longer
  operates as a standalone public-facing pharmaceutical company. There is no public developer program, OpenAPI specification,
  SDK, or technology API surface associated with Endo, the post-emergence Endo Inc, Keenova Therapeutics, or Par Health. Any
  references to "API" on the successor companies' sites refer to pharmaceutical Active Pharmaceutical Ingredients, not software
  application programming interfaces.
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.19'
apis: []
common:
- type: DomainSecurity
  url: security/endo-international-domain-security.yml
- type: Website
  url: https://www.endo.com
- type: SuccessorWebsite
  url: https://www.keenova.com
- type: SuccessorWebsite
  url: https://www.parhealth.com
- type: MergerPartnerWebsite
  url: https://www.mallinckrodt.com
- type: ChapterEleven
  url: https://restructuring.ra.kroll.com/endo
- type: OpioidSettlement
  url: https://nationalopioidsettlement.com
- type: LinkedIn
  url: https://www.linkedin.com/company/endo-international
- type: SECFilings
  url: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001593034
overlays:
- type: APIEvangelistRanking
  url: corporate-event-only
events:
- type: ChapterEleven
  date: '2022-08-16'
  description: Endo International plc and certain subsidiaries filed voluntary petitions for Chapter 11 in the US Bankruptcy
    Court for the Southern District of New York, citing opioid-related litigation and balance-sheet pressure.
- type: Emergence
  date: '2024-04-23'
  description: Endo emerged from Chapter 11 as Endo, Inc., a privately held company owned by its former creditors, with reduced
    debt and funded opioid settlement obligations.
- type: Merger
  date: '2025-07-31'
  description: Endo combined with Mallinckrodt to form a single specialty pharmaceuticals and generics group.
- type: Separation
  date: 2025-11
  description: The combined company separated into Keenova Therapeutics (specialty branded) and Par Health (generics, sterile
    injectables, pharmaceutical APIs).
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com